Tolerance for Novogen
Friday, 27 February, 2009
Interim results from a Phase II clinical trial in prostate cancer patients by Novogen’s subsidiary Marshall Edwards have shown the oral dose is well tolerated with no serious adverse events.
The US trial is studying the anti-tumour effects of phenoxodiol, an inhibitor of the pro-survival regulator sphingosine-1-phosphate (S-1-P).
Marshall Edwards is developing the product as a combination therapy for chemo-resistant ovarian cancer and as a monotherapy for cervical cancer.
The compound is also being studied as a monotherapy in prostate cancer, and in combination with the chemotherapy drugs cisplatin or carboplatin.
A study conducted by St George Hospital’s Professor Paul de Souza found phenoxodiol was able to enhance the activity of cisplatin and carboplatin in prostate cancer cells in vitro.
For the full story, see the March/April issue of Australian Life Scientist.
Novel antibiotic activates 'suicide' mechanism in superbug
Researchers have discovered a new class of antibiotic that selectively targets Neisseria...
Modifications in the placenta linked to psychiatric disorders
Schizophrenia, bipolar disorder and major depression disorder are the neuropsychiatric disorders...
ADHD may be linked with an increased risk of dementia
An adult brain affected by attention deficit hyperactivity disorder (ADHD) presents modifications...
